Drugs / Sodium 4-Phenylbutyrate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT00590538 Comparator | Feb 2003 → Dec 2008 | cystic fibrosis | Children's Hospital of Philadelphia | Terminated | No outcome recorded |
| Phase 1/2 | NCT00016744 Comparator | Sep 2001 → Oct 2005 | cystic fibrosis | Children's Hospital of Philadelphia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium 4-Phenylbutyrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00590538 ↗ |
| Known as | 4PBA | “Sodium 4-Phenylbutyrate (4PBA)” NCT00016744 ↗ |
| Action | Restore | “Both drugs may be able to restore normal chloride movements in body organs and glands.” NCT00016744 ↗ |
| Route | Oral | “The standard oral adult dose is 20g/day (tablets) for 4 days.” NCT00016744 ↗ |